Platelet Party? Let T-TAS® 01 be your designated driver.
Posted: July 8, 2021
Platelet Party? Let T-TAS® 01 be your designated driver. Use the leading edge in impaired primary hemostasis assessment and get results quickly with whole blood. The DiaPharma Group is excited to provide Fujimori Kogyo/Zacros’s T-TAS® 01 system – an automated microchip flow chamber system developed for the quantitative assessment of the thrombus formation process under physiologic flow conditions. The test requires few steps to run, whole-blood collection followed by transfer of 320 μL to a blood reservoir and attachment to test chip. Minimal pre-analytical handling and a simple to interpret numerical cut-off makes for a simple and reliable identification of patients with a primary hemostatic disorder or to measure the efficacy of any anti-platelet therapeutic in ten minutes or less from assay start.
The T-TAS® 01 is for the global evaluation of overall hemostatic ability using physiologic flow conditions, and is FDA-cleared for the analysis of platelet thrombus formation in those with impaired primary hemostatic function and for those on anti-platelet therapy. The T-TAS® 01 is sensitive to both aspirin and P2Y12 inhibition, as well as the various vWD subtypes and Glanzmann Thrombasthenia. Separate reagent kit or addition of exogenous agonists aren’t necessary.
It’s not just support. It’s solutions. Our scientific experts and customer support teams are just a call or click away. Explore our wide portfolio of hemostasis assays from DiaPharma. 1.800.447.3846 / email@example.com.